Although both CD19 and CD20 are eventually lost from the terminally differentiated plasma cells, CD20-negative B-cell lymphoma is rare, and CD19 deletion is a common cause of relapse after therapy [22, 23]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.